Skip to main content
ANAGENICS LIMITED logo

ANAGENICS LIMITED — Investor Relations & Filings

Ticker · AN1 ISIN · AU0000198095 ASX Manufacturing
Open in API
Filings indexed 1,067 across all filing types
Latest filing 2022-04-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX AN1

About ANAGENICS LIMITED

https://anagenics.com

Anagenics Limited is a health and wellness company focused on the development and commercialization of science-based anti-aging and longevity solutions. The company specializes in the research and distribution of clinically validated products targeting hair loss and skin health. Its core portfolio includes the évolis brand, which utilizes proprietary FGF5 inhibitor technology to promote hair growth and improve hair health. Through its subsidiaries, such as Advangen and BLC Cosmetics, the company manages a diverse range of premium skincare and wellness brands. Anagenics operates across international markets, providing consumer-facing products and professional-grade treatments backed by scientific research. The company's strategic focus remains on expanding its presence in the global beauty-tech and wellness sectors by leveraging its intellectual property and distribution networks.

Recent filings

Filing Released Lang Actions
Appendix 4C and Quarterly Activity Report 7 pages 294.3KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q3 FY2022 Business Activity Report' and includes detailed commentary on quarterly financial performance, cash flow statements, and operational updates. It contains unaudited financial figures for the quarter ended 31 March 2022, including revenue, cash flows from operating, investing, and financing activities, and cash balances. The presence of the Appendix 4C quarterly cash flow report, which is a regulatory requirement for Australian listed entities, confirms this is a quarterly financial report. The document is approximately 15,000 characters long and contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification, nor is it a full annual report or earnings release. Hence, the correct classification is IR with high confidence. Q3 2022
2022-04-27 English
New Leadership Driving Business Transformation 3 pages 139.9KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated March 16, 2022, from Anagenics Limited (ASX: AN1). It discusses recent leadership changes, strategic business transformation initiatives, cost savings, integration of an acquisition (BLC Cosmetics), and outlook for profitability and growth. The content focuses on operational updates, strategic review progress, and business outlook rather than presenting detailed financial statements or quarterly results. There is no indication of this being a full annual or interim report, earnings release, or audit report. It is not a call transcript or a voting result announcement. The document is a corporate update on management and business strategy changes, which aligns best with a Capital/Financing Update (CAP) category as it discusses business transformation and financial outlook related to leadership and strategic initiatives. The document length (6398 characters) and content do not suggest it is a report publication announcement or regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-03-15 English
Notification of cessation of securities - AN1 4 pages 24.4KB
Regulatory Filings Classification · 95% confidence The document is a notification about the cessation (lapse) of certain securities (options) of Anagenics Limited. It details the number of securities that have ceased, the reason for cessation, and the updated issued capital following these changes. The document is an announcement of changes in the company's securities, specifically about securities ceasing to exist due to conditions not being met. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about securities status and does not fit into more specific categories like capital changes (which usually involve new issues or buybacks) or director dealings. The document is relatively short (4010 characters) and is a formal notification to the exchange about securities cessation.
2022-03-01 English
Anagenics Appoints CEO 2 pages 139.8KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement about the appointment of a new CEO, Matthew Dudek, replacing the previous CEO. It includes details about his background, the company's strategic priorities, and a summary of his employment terms. There is no financial data, no discussion of financial results, no mention of annual or interim reports, no voting results, no legal proceedings, no capital changes, and no other regulatory filings. The content focuses solely on management changes at the board or senior executive level. Therefore, the document fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and is a direct announcement, not a report publication or certification. Hence, the classification is MANG with high confidence.
2022-02-28 English
Final Director's Interest Notice - Halasz 2 pages 230.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the securities holdings and interests of a director who has ceased to be a director, including shares and options held directly and indirectly. The document is a formal notification of a director's personal share transactions and interests, which aligns with the definition of Director's Dealing filings. The document length is 2600 characters, which is consistent with a notice rather than a full report. Therefore, the appropriate classification is Director's Dealing (DIRS).
2022-02-28 English
Anagenics Board and Leadership Transition 1 page 89
Board/Management Information Classification · 100% confidence The document is an ASX announcement titled 'ANAGENICS BOARD AND LEADERSHIP TRANSITION' dated 15 February 2022. It details changes in the company's board and senior management, including the appointment of a new Non-executive Chairman, the resignation of the previous Chairman, and the CEO's planned transition out of her roles. There is no financial data, no mention of financial results, or regulatory filings related to financial performance. The content focuses solely on changes in the board and management team. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 3196 characters, which is consistent with a typical announcement of management changes rather than a full report or detailed filing.
2022-02-14 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.